FIELD: pharmacology.
SUBSTANCE: invention relates to organic chemistry, namely a heterocyclic compound of formula 
(I) or to a therapeutically acceptable salt thereof, where X is benzo[d]thiazolyl, thiazolo[5,4-b]pyridinyl, thiazolo[4,5-c]pyridinyl, imidazo[1,2-a]pyridinyl, thiazolo[5,4-c]pyridinyl, thiazolo[4,5-b]pyridinyl, imidazo[1,2-a]pyrazinyl or imidazo[ 1,2-b]pyridazinyl; Y1 means pyrrolyl, pyrazolyl, triazolyl or pyridinyl; where Y1 is optionally substituted with 1 or 2 substituents independently selected from R5, CN and Cl; L1 is selected from (CR6R7)q, (CR6R7)s-O-(CR6R7)r, (CR6R7)s-S-(CR6R7)r, (CR6R7)s-S(O)2-(CR6R7)r and (CR6R7)s-NR6A-(CR6R7)r; Y2 means mono- or tricyclic C8-C10-cycloalkyl, spiro[2.5]octyl, spiro[3.5]nonyl, oxatricyclo[3.3.1.13,7]decyl or azabicyclo[3.2.1]octyl; where Y2 is optionally substituted with 1, 2 or 3 substituents independently selected from R8, OR8, SO2R8, CO(O)R8, OH and Br; Z1 is selected from 
, R1 and R3 are absent; R2 is deuterium or C1-C6-alkyl; R5 is C1-C6-alkyl; R6A is selected from hydrogen and C1-C6-alkyl; each R6 and R7 are hydrogen; R8 is selected from the group consisting of C1-C3-alkyl, morpholinyl and dioxydothiomorpholinyl; where R8, meaning C1-C6-alkyl, is optionally substituted with a substituent selected from R16, OR16, SO2R16 and NHR16; Rk is selected from C1-C6-alkyl, morpholinyl, cyclopropyl and C1-haloalkyl; R16 Is selected from C1-C4-alkyl, phenyl, morpholinyl and tetrahydropyranyl; where R16, meaning C1-C4-alkyl, is optionally substituted with 1 substituent selected from OCH3, OCH2CH2OCH3 and OCH2CH2NHCH3; q is 1 or 2; s, m and p is 0; r is 0 or 1; N is 0, 1, or 2. The invention also relates to specific compounds, pharmaceutical compositions based on these compounds and a method for treatment of these diseases.
EFFECT: new heterocyclic compounds are obtained, that are useful for treatment of some cancers.
16 cl, 3 tbl, 86 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENTS CAUSING APOPTOSIS AND INTENDED FOR TREATING CANCER, IMMUNE AND AUTOIMMUNE DISEASES | 2012 |
|
RU2594282C2 |
| ANTIBODIES TO B7-H3 AND CONJUGATES OF ANTIBODY AND DRUG | 2017 |
|
RU2764651C2 |
| HETEROCYCLIC COMPOUNDS AND METHODS OF APPLICATION | 2009 |
|
RU2525116C2 |
| NOVEL PYRROLE COMPOUNDS, SYNTHESIS METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | 2014 |
|
RU2607788C2 |
| AZAADAMANTANE DERIVATIVES AND METHODS FOR APPLYING | 2007 |
|
RU2450002C2 |
| BETA-LACTAMASE INHIBITORS | 2013 |
|
RU2654692C2 |
| NOVEL PHOSPHATE COMPOUNDS, SYNTHESIS METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | 2014 |
|
RU2617682C2 |
| DERIVATIVES OF BENZIMIDAZOL INHIBITING FACTOR Xa | 2004 |
|
RU2346944C2 |
| AZAINDOL DERIVATIVES AS FACTOR Xa INHIBITORS | 2004 |
|
RU2330853C2 |
| COMPOUNDS AND METHODS FOR USING | 2009 |
|
RU2561109C2 |
